Navigation Links


MEM in Medical Technology

Memory Pharmaceuticals Achieves Enrollment Goal for Phase 2 Study of MEM 3454 in Cognitive Impairment Associated With Schizophrenia

-Triggers $5 Million Payment from Roche- MONTVALE, N.J., Nov. 19 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. (Nasdaq: MEMY ) today announced that it has achieved the enrollment goal for its Phase 2 trial of R3487/MEM 3454, its lead alpha-7 nicotinic receptor agonist, in cogni...

Roche Exercises its Option to Further Develop and Commercialize Memory Pharmaceuticals' Nicotinic Alpha-7 Agonist, MEM 3454

-Memory Receives $6 Million Milestone Payment- -Memory to Host Conference Call at 9:00 a.m. EDT Today- MONTVALE, N.J. and BASEL, Switzerland, May 2 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. (Nasdaq: MEMY ) and Roche (SWX: ROG) today announced that Roche has ex...

Memory Pharmaceuticals & Roche Expand Development Program for MEM 3454 in Schizophrenia

- Establishes Plan for Biomarker Study - MONTVALE, N.J., Feb. 19 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. (Nasdaq: MEMY ) today announced that it plans to conduct a clinical study of MEM 3454, the Company's lead nicotinic alpha-7 partial agonist, on two biomarker...

Memory Pharmaceuticals Announces Results for Phase 2a Trial of MEM 1003 in Alzheimer's Disease

-Company to Host Conference Call at 9:00 a.m. EDT- MONTVALE, N.J., Oct. 15 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. (Nasdaq: MEMY ) today announced top-line data from the multi-center, randomized, double-blind, placebo-controlled Phase 2a study of MEM 1003, a neuronal...

Memory Pharmaceuticals Highlights Progress with Key Programs at its R&D Day

...munity. The Company reported new clinical data for mem 1414, its lead PDE4 inhibitor, demonstrating the c... in humans. In addition, the Company has nominated mem 68626 as the lead development candidate from its 5...r, we are pleased to report that we have nominated mem 68626 as the lead compound in our 5-HT6 antagonist...

Memory Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Financial Results

...ths, highlighted by our positive Phase 2a data for mem 3454 in Alzheimer's disease, the expansion of our schizophrenia development program for mem 3454 with our partner Roche, and the completion of...4996/MEM 63908, and initiate a biomarker study for mem 3454 in schizophrenia." Financial Results For ...
MEM in Biological Technology

Memory Pharmaceuticals Initiates Phase 2a Trial of MEM 3454 in Cognitive Impairment Associated with Schizophrenia

MONTVALE, N.J., Dec. 20 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. (Nasdaq: MEMY ) today announced dosing of the first subject in a randomized, double-blind, placebo-controlled Phase 2a clinical trial of MEM 3454, the Company's lead nicotinic alpha-7 receptor partial agonist, in c...

Double Helix Strengthens its Strategic Pricing and Reimbursement Practice with Hire of Caryn Zieses

... previous client services experience in the Equity Research division of Lehman Brothers. Caryn holds an MBA from the Kellogg School of Management, an mem from Northwestern University, and a BSE in Chemical Engineering from the University of Pennsylvania. http://www.doublehelixdevelopment.c...

Memory Pharmaceuticals Reports Third Quarter 2008 Financial Results

...E10 inhibitor program and from SMRI related to the mem 1003 program which were recognized in 2007 but not...administrative costs and costs associated with the mem 1003 program. General and administrative expense...ory Pharmaceuticals presented preclinical data for mem 68626, its lead 5-HT6 antagonist, in a poster pres...

Memory Pharmaceuticals Reports First Quarter 2008 Financial Results

...nd our Phase 1 program for R4996/MEM 63908, initiating a Phase 2a trial for mem 1414, and advancing our 5-HT6 antagonist program into the clinic." Financ... $3.4 million decrease in costs associated with the clinical development of mem 1003. General and administrative expenses for the quarter ended March 31,...

Memory Pharmaceuticals Refocuses to Advance Development and Clinical Programs

...lpha-7 Receptor Agonist Collaboration with Roche. mem 3454, the lead compound in the Company's ni...y expects to initiate a biomarker study for mem 3454 in schizophrenia this summer, with res...expects to complete its Phase 1 program for mem 63908 and report top-line results in the fourth qu...

Neurobiological Technologies Announces Pricing of Its $60 Million Common Stock Offering

...will receive approximately $55 million of net offering proceeds, after underwriting discounts and estimated costs. Merriman Curhan Ford & Co. (Amex: mem ) acted as the sole book-running manager in this offering, and Dawson James Securities, Inc. acted as co-manager. Copies of the final prospectus may ...

Agendia BV Appoints Clinical and Scientific Advisory Board

...esearch programs and provide critical evaluations from academic and clinical perspectives. Agendia welcomes: Piet Borst (chair), M.D., PhD, CBE, For mem RS, Staff Member and Emeritus Director of the Netherlands Cancer Institute and Professor of Clinical Biochemistry, Amsterdam, The Netherlands Jose Ba...

Bionovo Announces Proposed Public Offering of Common Stock

...al Markets Corp. and Canaccord Adams Inc. are acting as joint book-running managers for the proposed offering, with Merriman Curhan Ford & Co. (Amex: mem ) acting as a co-manager. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sal...

Screening for β2-adrenergic receptor agonists using the pH-sensitive dye,CypHer5, and the IN Cell Analyzer 3000

... LOPAC (Sigma)

Culture medium: mem (Sigma) containing 10% (v/v) FBS, 200 µ g/ml G418, L-glutamine, non-essential amino acids

Assay medium: mem (Sigma)

Agonist: Isoproterenol (Sigma) ...

The use of CypHer5E and the IN Cell Analyzer 1000 for live-cell receptor internalization studies

...EK293 cell line expressing EGF receptor HEK Culture medium: mem (Sigma M2279) containing: 10% (v/v) FBS Geneticin G418...

4. Replace the culture medium with 100 µl/well of fresh mem (phenol red free) containing 2.5–5 µg/ml CypHer5E anti-VSV-G an...

More>>

Other TagsAngelsInfertilityInfertilityStrategyStrategyStrategy
(Date:11/30/2009)..., Nov. 30 SEIU Local 21... corporation Sodexo will hold a rally Tuesday, Dec...nance headquarters, 3800 Desire Parkway, New Orlea...bitrary disciplinary policies that target employee...y member. Sodexo employees who clean schools in th...
(Date:11/30/2009)... , Study Uses Tent To Simulate High Altitud...RNewswire-USNewswire/ -- Distance runners who live...n to improve their performance during races in are...ents, who suffer from fatigue, improve their exerc...titude simulator? ,, That is the question being...
(Date:11/30/2009)...EAPOLIS, Nov. 30 The Eject Helmet ...required equipment in the Top Fuel, Funny Car, Pro... National Hot Rod Association (NHRA) Full Throttle...agster and Top Alcohol Funny Car drivers in the NH...ly product that allows medical caregivers at race ...
(Date:11/30/2009)...er 30, 2009 ― Providing free medications to ...nts, lives at a relatively low cost for provincial...ers at St. Michael,s Hospital in Toronto. , "Ma...cribed medications because they simply don,t fill ...tudy,s lead author and a physician at St. Michael,...
(Date:11/30/2009)...ORK, Nov. 30 Reportlinker.com anno...le in its catalogue: ,, Key Players and Innova...ies in ingredients, pharma, food and drinks ,,...-and-Innovative-Start-Ups-in-Nutraceuticals-Emergi...s.html ,, Nutraceuticals are bioactive compoun...
Breaking Medicine News(10 mins):Health News:As H1NI Hits New Orleans in Force: School Custodians to Hold Rally to Call on Contractor to Stop Penalizing Workers Coping With Illness 2Health News:Can Exposure to Low Oxygen Levels Benefit Heart Failure Patients? 2Health News:Can Exposure to Low Oxygen Levels Benefit Heart Failure Patients? 3Health News:Can Exposure to Low Oxygen Levels Benefit Heart Failure Patients? 4Health News:National Hot Rod Association Mandates Eject Helmet Removal System for 2010 2Health News:Coverage of inexpensive drugs may increase length and quality of life after heart attack 2Health News:Reportlinker Adds Key Players and Innovative Start-Ups in Nutraceuticals: Emerging Strategies in Ingredients, Pharma, Food and Drinks 2Health News:Reportlinker Adds Key Players and Innovative Start-Ups in Nutraceuticals: Emerging Strategies in Ingredients, Pharma, Food and Drinks 3Health News:Reportlinker Adds Key Players and Innovative Start-Ups in Nutraceuticals: Emerging Strategies in Ingredients, Pharma, Food and Drinks 4Health News:Reportlinker Adds Key Players and Innovative Start-Ups in Nutraceuticals: Emerging Strategies in Ingredients, Pharma, Food and Drinks 5Health News:Reportlinker Adds Key Players and Innovative Start-Ups in Nutraceuticals: Emerging Strategies in Ingredients, Pharma, Food and Drinks 6
(Date:11/30/2009)... Orleans, LA Researchers from LSU Health Sciences...e Kennedy Shriver National Institute of Child Heal...f Public Health, Brigham and Women,s Hospital, and...time that drinking more than 5 servings of sugar- ...o significantly elevate the risk of developing dia...
(Date:11/30/2009)... Editors of The Journal of Experimental Biology ... Centre National de la Recherche Scientifique (CNR...e winner of this year,s JEB Outstanding Paper Pr...tstanding achievement and is intended to encourage... Editor-in-Chief, and adds that ,we truly apprecia...
(Date:11/30/2009)... so-called invasion proteins are crucial for infec...e of human cells, which stimulates the host cell t...olecules exert a different function, for example t...e group,s results have now been published in the c... ". , Spoiled meat is one of the sources for Li...
Breaking Biology News(10 mins):Sugary cola drinks linked for first time to higher risk of gestational diabetes 2Sugary cola drinks linked for first time to higher risk of gestational diabetes 3French scientist wins the Journal of Experimental Biology Outstanding Paper Prize 2009 2French scientist wins the Journal of Experimental Biology Outstanding Paper Prize 2009 3French scientist wins the Journal of Experimental Biology Outstanding Paper Prize 2009 4It takes 2 to infect 2Mindray Medical to Participate in the SIG Third Annual Beijing Management Summit 55505 1Mindray Medical to Participate in the SIG Third Annual Beijing Management Summit 55505 2CVS Caremark Data Finds More than 50 Percent of Adults 45 years and Younger are not Adherent to Cholesterol Lowering Medications 55501 1CVS Caremark Data Finds More than 50 Percent of Adults 45 years and Younger are not Adherent to Cholesterol Lowering Medications 55501 2CVS Caremark Data Finds More than 50 Percent of Adults 45 years and Younger are not Adherent to Cholesterol Lowering Medications 55501 3Upsher Smith Launches New Website for Divigel 28R 29 a Bioidentical and FDA Approved Hormone Therapy for Moderate to Severe Hot Flashes Including Ni 55497 1Upsher Smith Launches New Website for Divigel 28R 29 a Bioidentical and FDA Approved Hormone Therapy for Moderate to Severe Hot Flashes Including Ni 55497 2Upsher Smith Launches New Website for Divigel 28R 29 a Bioidentical and FDA Approved Hormone Therapy for Moderate to Severe Hot Flashes Including Ni 55497 3Upsher Smith Launches New Website for Divigel 28R 29 a Bioidentical and FDA Approved Hormone Therapy for Moderate to Severe Hot Flashes Including Ni 55497 4
Other Contentscobaltcobaltcobalamintartarcoalcoalcoalcoalcocainecocainecocainecoccyximplantimplantimplantimplantimplant